File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1177/1758835920927850
- Scopus: eid_2-s2.0-85085888147
- WOS: WOS:000539246500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The functional role of long noncoding RNA in resistance to anticancer treatment
Title | The functional role of long noncoding RNA in resistance to anticancer treatment |
---|---|
Authors | |
Keywords | cancer drug resistance EMT long noncoding RNAs mechanisms |
Issue Date | 2020 |
Publisher | SAGE Publications (UK and US): Open Access Titles. The Journal's web site is located at https://journals.sagepub.com/home/tama |
Citation | Therapeutic Advances in Medical Oncology, 2020, v. 12, p. article no. 1758835920927850 How to Cite? |
Abstract | Chemotherapy is one of the fundamental methods of cancer treatment. However, drug resistance remains the main cause of clinical treatment failure. We comprehensively review the newly identified roles of long noncoding RNAs (lncRNAs) in oncobiology that are associated with drug resistance. The expression of lncRNAs is tissue-specific and often dysregulated in human cancers. Accumulating evidence suggests that lncRNAs are involved in chemoresistance of cancer cells. The main lncRNA-driven mechanisms of chemoresistance include regulation of drug efflux, DNA damage repair, cell cycle, apoptosis, epithelial-mesenchymal transition (EMT), induction of signaling pathways, and angiogenesis. LncRNA-driven mechanisms of resistance to various antineoplastic agents have been studied extensively. There are unique mechanisms of resistance against different types of drugs, and each mechanism may have more than one contributing factor. We summarize the emerging strategies that can be used to overcome the technical challenges in studying and addressing lncRNA-mediated drug resistance. |
Persistent Identifier | http://hdl.handle.net/10722/284280 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 1.529 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | QU, Y | - |
dc.contributor.author | Tan, HY | - |
dc.contributor.author | Chan, YT | - |
dc.contributor.author | JIANG, H | - |
dc.contributor.author | Wang, N | - |
dc.contributor.author | WANG, D | - |
dc.date.accessioned | 2020-07-20T05:57:28Z | - |
dc.date.available | 2020-07-20T05:57:28Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Therapeutic Advances in Medical Oncology, 2020, v. 12, p. article no. 1758835920927850 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | http://hdl.handle.net/10722/284280 | - |
dc.description.abstract | Chemotherapy is one of the fundamental methods of cancer treatment. However, drug resistance remains the main cause of clinical treatment failure. We comprehensively review the newly identified roles of long noncoding RNAs (lncRNAs) in oncobiology that are associated with drug resistance. The expression of lncRNAs is tissue-specific and often dysregulated in human cancers. Accumulating evidence suggests that lncRNAs are involved in chemoresistance of cancer cells. The main lncRNA-driven mechanisms of chemoresistance include regulation of drug efflux, DNA damage repair, cell cycle, apoptosis, epithelial-mesenchymal transition (EMT), induction of signaling pathways, and angiogenesis. LncRNA-driven mechanisms of resistance to various antineoplastic agents have been studied extensively. There are unique mechanisms of resistance against different types of drugs, and each mechanism may have more than one contributing factor. We summarize the emerging strategies that can be used to overcome the technical challenges in studying and addressing lncRNA-mediated drug resistance. | - |
dc.language | eng | - |
dc.publisher | SAGE Publications (UK and US): Open Access Titles. The Journal's web site is located at https://journals.sagepub.com/home/tama | - |
dc.relation.ispartof | Therapeutic Advances in Medical Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | cancer | - |
dc.subject | drug resistance | - |
dc.subject | EMT | - |
dc.subject | long noncoding RNAs | - |
dc.subject | mechanisms | - |
dc.title | The functional role of long noncoding RNA in resistance to anticancer treatment | - |
dc.type | Article | - |
dc.identifier.email | Tan, HY: hyhtan@hku.hk | - |
dc.identifier.email | Chan, YT: ecyt1@hku.hk | - |
dc.identifier.email | Wang, N: ckwang@hku.hk | - |
dc.identifier.authority | Wang, N=rp02075 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1177/1758835920927850 | - |
dc.identifier.scopus | eid_2-s2.0-85085888147 | - |
dc.identifier.hkuros | 311483 | - |
dc.identifier.volume | 12 | - |
dc.identifier.spage | article no. 1758835920927850 | - |
dc.identifier.epage | article no. 1758835920927850 | - |
dc.identifier.isi | WOS:000539246500001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1758-8340 | - |